

EFFECTIVE DATE: 7|01|2022

POLICY LAST UPDATED: 8|22|2022

OVERVIEW

Calprotectin is a calcium and zinc-binding protein that is a potential marker of intestinal inflammation. Fecal calprotectin testing is proposed as a noninvasive means to diagnose inflammatory bowel disease (IBD). Other potential uses are to evaluate treatment response for patients with IBD and as a marker of relapse.

Calprotectin is a calcium- and zinc-binding protein that is a potential marker of intestinal inflammation. Fecal calprotectin testing is proposed as a noninvasive means to diagnose inflammatory bowel disease (IBD). Other potential uses are to evaluate treatment response for patients with IBD and as a marker of relapse.

MEDICAL CRITERIA

Not applicable

PRIOR AUTHORIZATION

Not applicable

POLICY STATEMENT

Medicare Advantage Plans

Fecal calprotectin testing is considered medically necessary for the evaluation of patients when the differential diagnosis is inflammatory bowel disease or noninflammatory bowel disease (including irritable bowel syndrome) for whom endoscopy with biopsy is being considered.

Fecal calprotectin testing is considered not covered in the management of inflammatory bowel disease, including the management of active inflammatory bowel disease and surveillance for relapse of disease in remission as the evidence is insufficient to determine the effects of the technology on health outcomes.

Commercial Products

Fecal calprotectin testing is considered medically necessary for the evaluation of patients when the differential diagnosis is inflammatory bowel disease or noninflammatory bowel disease (including irritable bowel syndrome) for whom endoscopy with biopsy is being considered.

Fecal calprotectin testing is considered not medically necessary in the management of inflammatory bowel disease, including the management of active inflammatory bowel disease and surveillance for relapse of disease in remission as the evidence is insufficient to determine the effects of the technology on health outcomes.

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable laboratory not medically necessary/not covered benefits/coverage.

BACKGROUND

Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is a chronic condition that encompasses 2 main forms: Crohn disease and ulcerative colitis. These conditions overlap in clinical and pathologic characteristics but have distinct features. Crohn disease can involve the entire gastrointestinal (GI) tract and is characterized by transmural inflammation. Ulcerative colitis involves inflammation limited to the mucosal layer of the colon, almost always involving the rectum.

IBD is suggested by the presence of 1 or more of a variety of signs and symptoms that can be GI (eg, abdominal pain, bloody diarrhea, perianal fistulae), systemic (eg, weight loss, fatigue, growth failure in children), or extraintestinal (eg, characteristic rashes, uveitis, arthritis) in nature. Patients may present with or develop a range of severity of symptoms in the disease course, including life-threatening illness.

Diagnosis

Diagnosing IBD is associated with well-defined management changes. A typical diagnostic approach to IBD includes stool testing for enteric pathogens, blood tests (complete blood count, inflammatory markers) to differentiate etiologies and evaluate disease severity, as well as small bowel imaging and endoscopy (upper GI, colonoscopy) with biopsies.

Fecal Calprotectin

In some cases, the clinical manifestations of IBD can be non-specific and suggestive of other disorders, including infectious colitis, colon cancer, and functional bowel disorders, including irritable bowel syndrome (IBS).

Thus, there is a need for simple, accurate, noninvasive tests to detect intestinal inflammation. Potential noninvasive markers of inflammation fall into several categories, including serologic and fecal. Serologic markers such as C-reactive protein and anti-neutrophil cytoplasmic antibodies tend to have low sensitivity and specificity for intestinal inflammation because they are affected by inflammation outside the GI tract. Fecal markers, in contrast, have the potential to be more specific to the diagnosis of GI tract disorders, because their levels are not elevated in extra-digestive processes. Fecal leukocyte testing has been used to evaluate whether there is intestinal mucosal inflammation. The level of fecal leukocytes can be determined by the microscopic examination of fecal specimens; however, leukocytes are unstable and must be evaluated promptly by skilled personnel. There is interest in identifying stable proteins in stool specimens, which may be representative of the presence of leukocytes, rather than evaluating leukocyte levels directly.

Calprotectin is a protein that could be used as a marker of inflammation. It is a calcium- and zinc-binding protein that accounts for approximately 60% of the neutrophil's cytoplasmic proteins. It is released from neutrophils during activation or apoptosis/necrosis and has a role in regulating inflammatory processes. In addition to potentially higher sensitivity and specificity than serologic markers, another advantage of calprotectin as a marker is that it has been shown to be stable in feces at room temperature for up to 1 week, leaving enough time for patients to collect samples at home and send them to a laboratory for testing. In contrast, lactoferrin, another potential fecal marker of intestinal inflammation, is stable at room temperature for about 2 days.

Among potential disadvantages of fecal calprotectin as a marker of inflammation are that fecal calprotectin levels increase after the use of nonsteroidal anti-inflammatory drugs, that levels may change with age, and that bleeding (eg, nasal, menstrual) may cause an elevated fecal calprotectin level. Moreover, there is uncertainty about the optimal cutoff to distinguish between IBD and noninflammatory disease.

Fecal calprotectin testing has been used to differentiate between organic (eg, inflammation) and functional (no visible problem in the GI tract like IBS) disease. Some consider fecal calprotectin to be a marker of neutrophilic intestinal inflammation rather than a marker of organic disease and believe it has utility to distinguish between IBD and non-IBD. In practice, the test might be suitable for selecting patients with IBD symptoms for endoscopy (ie, deciding which patients do not require endoscopy). Fecal calprotectin testing has also been proposed to evaluate the response to IBD treatment and for predicting relapse. If found to be

sufficiently accurate, results of calprotectin testing could be used to change treatment, such as adjusting medication levels.

Treatment

Guideline-based treatments of IBD include oral and rectal salicylates, glucocorticoids, immunomodulators (eg, methotrexate), and multiple biologic therapies (eg, infliximab), depending on disease severity.

For individuals who have a suspicion of IBD when endoscopy with biopsy is being considered who receive fecal calprotectin testing to select patients who can forgo endoscopy, the evidence includes prospective and retrospective diagnostic accuracy studies and systematic reviews. Relevant outcomes are test validity, symptoms, change in disease status, quality of life (QOL), hospitalizations, and medication use. Twenty-eight studies in a systematic review evaluated the diagnostic accuracy of fecal calprotectin in patients suspected of having IBD for whom noninflammatory bowel disease, such as IBS, remains a consideration. Studies varied in the fecal calprotectin protein level cutoff used to indicate the presence of disease, but most used a cutoff of 50 µg/g, which is the recommended lower bound. Studies have indicated that, at this threshold, the test has a sensitivity of 93% to 99% for IBD and a negative predictive value of 73% to 100% for intestinal inflammation. Out of 100 cases of suspected IBD, approximately 49 invasive tests would be avoided with 1 case missed. In another more recent meta-analysis involving 19 studies where the majority of studies again used the cutoff of 50 µg/g, investigators determined that out of 100 hypothetical patients, 18 non-disease patients would have a colonoscopy performed and 1 patient with IBD would not be referred for a colonoscopy. Additionally, it was determined that incorporating a fecal calprotectin test into the regular diagnostic work-up would reduce the need for colonoscopy by 66.7%. Therefore, fecal calprotectin can be used to inform a decision of whether to proceed with endoscopy. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have active IBD who receive fecal calprotectin testing to monitor disease activity, the evidence includes a systematic review and 2 randomized controlled trials (RCTs). Relevant outcomes are test validity, symptoms, change in disease status, QOL, hospitalizations, and medication use. A systematic review determined that a fecal calprotectin level of 50 µg/g was the optimum threshold for triaging patients for endoscopy when they have symptoms of active disease. RCTs are needed to determine whether guiding treatment based on fecal calprotectin levels can improve disease management. A 2017 RCT included fecal calprotectin as 1 of several indicators of inflammation to test the effect of tight control of IBD on health outcomes. The independent contribution of fecal calprotectin could not be determined from this study design. In another RCT, self-monitoring with a home-based fecal calprotectin test among patients with established IBD demonstrated an increase in the proportion of patients seeking medical treatment; compliance to home-based testing in this study was low (29%). The use of a home-based fecal calprotectin test that is not available in the US limits the applicability of this study. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have IBD in remission who receive fecal calprotectin testing to predict relapse, the evidence includes a systematic review and an RCT. Relevant outcomes are test validity, symptoms, change in disease status, QOL, hospitalizations, and medication use. A systematic review of studies that monitored fecal calprotectin in patients in remission demonstrated that fecal calprotectin levels began to rise 2 to 3 months before clinical relapse; an ideal fecal calprotectin cutoff for monitoring purposes was not identified. One RCT found no significant difference in the rate of relapse in patients whose medication was modified based on fecal calprotectin or standard clinical indicators, however, this RCT had design and conduct limitations that affected the interpretation of its results. Additional high-quality RCTs are needed to determine whether adding fecal calprotectin to standard clinical practice improves the management of IBD patients in remission. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

CODING

Medicare Advantage Plans and Commercial Products

The following CPT code is considered medically necessary when filed with the ICD-10 diagnosis codes listed below.

83993 Calprotectin, fecal

ICD-10 Diagnosis Codes that may support medical necessity:

K52.3

K52.89

K52.9

K58.0 - K58.9 I

R19.4

R19.5

R19.7

R19.8

RELATED POLICIES

Not applicable

PUBLISHED

Provider Update, May 2022

Provider Update, April 2021

Provider Update, April 2020

Provider Update, June 2019

Provider Update, February 2019

REFERENCES

1. ALPCO. Now Available: 510(k) Cleared Fecal Calprotectin ELISA. ALPCO website. Accessed October 31, 2021. <https://www.alpco.com/now-available-510k-cleared-fecal-calprotectin-elisa>
2. Petryszyn P, Staniak A, Wolosińska A, et al. Faecal calprotectin as a diagnostic marker of inflammatory bowel disease in patients with gastrointestinal symptoms: meta-analysis. *Eur J Gastroenterol Hepatol*. Nov 2019; 31(11): 1306-1312. PMID 31464777
3. Waugh N, Cummins E, Royle P, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. *Health Technol Assess*. Nov 2013; 17(55): xv-xix, 1-211. PMID 24286461
4. Otten CM, Kok L, Witteman BJ, et al. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome. *Clin Chem Lab Med*. 2008; 46(9): 1275-80. PMID 18597588
5. Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. *Inflamm Bowel Dis*. Jan 2008; 14(1): 32-9. PMID 17924558
6. Basumani P, Bardhan K, Eyre R, et al. Faecal calprotectin: Rotherham experience (unpublished slide presentation). BSG Away; 2012 June 28.
7. Li XG, Lu YM, Gu F, et al. [Fecal calprotectin in differential diagnosis of irritable bowel syndrome]. *Beijing Da Xue Xue Bao Yi Xue Ban*. Jun 18 2006; 38(3): 310-3. PMID 16778979
8. El-Badry A, Sedrak H, Rashed L. Faecal calprotectin in differentiating between functional and organic bowel diseases. *Arab J Gastroenterol*. May 23 2010;11(2):70-73.
9. Van de Vijver E, Schreuder AB, Cnossen WR, et al. Safely ruling out inflammatory bowel disease in children and teenagers without referral for endoscopy. *Arch Dis Child*. Dec 2012; 97(12): 1014-8. PMID 23019289
10. Sidler MA, Leach ST, Day AS. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. *Inflamm Bowel Dis*. Mar 2008; 14(3): 359-66. PMID 18050298

11. Damms A, Bischoff SC. Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases. *Int J Colorectal Dis.* Oct 2008; 23(10): 985-92. PMID 18629518
12. Henderson P, Casey A, Lawrence SJ, et al. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease. *Am J Gastroenterol.* Jun 2012; 107(6): 941-9. PMID 22370604
13. Bonnin Tomas A, Vila Vidal M, Rosell Camps A. [Fecal calprotectin as a biomarker to distinguish between organic and functional gastrointestinal disease]. *Rev Esp Enferm Dig.* Dec 2007; 99(12): 689-93. PMID 18290691
14. Fagerberg UL, Loof L, Myrdal U, et al. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. *J Pediatr Gastroenterol Nutr.* Apr 2005; 40(4): 450-5. PMID 15795593
15. Jorgensen LG, Fredholm L, Hyltoft Petersen P, et al. How accurate are clinical activity indices for scoring of disease activity in inflammatory bowel disease (IBD)? *Clin Chem Lab Med.* 2005; 43(4): 403-11. PMID 15899657
16. Mosli MH, Zou G, Garg SK, et al. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. *Am J Gastroenterol.* Jun 2015; 110(6): 802-19; quiz 820. PMID 25964225
17. Ostlund I, Werner M, Karling P. Self-monitoring with home based fecal calprotectin is associated with increased medical treatment. A randomized controlled trial on patients with inflammatory bowel disease. *Scand J Gastroenterol.* Jan 2021; 56(1): 38-45. PMID 33284639
18. Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. *Lancet.* Dec 23 2017; 390(10114): 2779-2789. PMID 29096949
19. Heida A, Park KT, van Rheezen PF. Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide. *Inflamm Bowel Dis.* Jun 2017; 23(6): 894-902. PMID 28511198
20. Lasso A, Ohman L, Stotzer PO, et al. Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study. *United European Gastroenterol J.* Feb 2015; 3(1): 72-9. PMID 25653861
21. Colombel JF, Shin A, Gibson PR. AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review. *Clin Gastroenterol Hepatol.* Feb 2019; 17(3): 380-390.e1. PMID 30099108
22. Smalley W, Falck-Ytter C, Carrasco-Labra A, et al. Spotlight: Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D). *Gastroenterology.* Sep 2019; 157(3): 858. PMID 31377275
23. Ananthakrishnan AN, Nguyen GC, Bernstein CN. AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Elderly Patients: Expert Review. *Gastroenterology.* Jan 2021; 160(1): 445-451. PMID 33011177
24. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol.* Apr 2018; 113(4): 481-517. PMID 29610508
25. Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. *Am J Gastroenterol.* Jan 01 2021; 116(1): 17-44. PMID 33315591
26. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. *Gastroenterology.* Apr 2021; 160(5): 1570-1583. PMID 33359090
27. National Institute Health Care Excellence (NICE). Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel. NICE website. October 2, 2013. Accessed October 31, 2021.

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

